Metformin Linked to Increased Risk of Acute Dialysis in T2DM

This article originally appeared here.
Metformin-associated 1-year risk of acute dialysis increased by 50.3 per 100,000 individuals.
Metformin-associated 1-year risk of acute dialysis increased by 50.3 per 100,000 individuals.

(HealthDay News) -- For patients with type 2 diabetes, metformin is associated with about a 50% increase in the risk of acute dialysis compared to sulfonylureas, according to a study published online in Diabetes, Obesity and Metabolism.

Nicholas Carlson, MD, from Copenhagen University in Denmark, and colleagues conducted a retrospective nationwide cohort study involving 168,443 drug-naive patients with type 2 diabetes aged 50 years and older. Participants initiated treatment with metformin or sulfonylurea between 2000 and 2012 (70.7% initiated treatment with metformin).

The researchers found that the 1-year risk for acute dialysis was 92.4 per 100,000 for sulfonylurea and 142.7 per 100,000 for metformin. The 1-year risk of acute dialysis associated with metformin was increased by 50.3 per 100,000 (risk ratio, 1.53; number needed to harm, 1,988).

"In a retrospective nationwide cohort study on the risk of acute dialysis associated with initiation of metformin in patients with type 2 diabetes, treatment with metformin was associated with a 50% increase in risk of acute dialysis compared with sulfonylurea," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Source

1. Carlson N, Hommel K, lesen JB, et al. Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study. Diabetes Obes Metab. doi: 10.1111/dom.12764.

Loading links....

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.